Free tool
FAERS Monitor: Rezzayo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217417 or its brand name (Rezzayo, Rezafungin Acetate). Reports on generic versions are filed under their own applications.
Reports
101
Serious
46
46% of reports
Hospitalization
19
Death reported
18
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use41
- product prescribing issue12
- no adverse event11
- drug ineffective9
- death6
- renal impairment5
- condition aggravated4
- fungal infection4
- product dose omission issue4
- product use issue4
- blood bilirubin increased3
- candida infection3
- cerebral haemorrhage3
- cholecystitis acute3
- dizziness3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 58 |
| 2025 | 10 |
| 2026 | 29 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,058 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product prescribing issueSignal | 12 | 114.8 | 67.5 | 1,243 |
| cholecystitis acuteSignal | 3 | 110.3 | 36.2 | 225 |
| candida infectionSignal | 3 | 37.0 | 12.1 | 72 |
| fungal infectionSignal | 4 | 25.0 | 9.6 | 70 |
| blood bilirubin increasedSignal | 3 | 23.1 | 7.6 | 43 |
| cerebral haemorrhageSignal | 3 | 17.5 | 5.7 | 32 |
| no adverse eventSignal | 11 | 12.6 | 7.2 | 108 |
| renal impairmentSignal | 5 | 12.4 | 5.3 | 42 |
| off label useSignal | 41 | 9.8 | 7.7 | 327 |
| product use issueSignal | 4 | 4.4 | 1.7 | 8 |
| product dose omission issue | 4 | 2.8 | 1.1 | 3 |
| condition aggravated | 4 | 2.7 | 1.0 | 3 |
| death | 6 | 1.5 | 0.7 | 0 |
| drug ineffective | 9 | 1.4 | 0.8 | 1 |
| dizziness | 3 | 1.3 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.